Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Joyce Fu Liu, M.D.

Co-Author

This page shows the publications co-authored by Joyce Liu and Ursula Matulonis.
Connection Strength

10.184
  1. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 Apr; 30(4):551-557.
    View in: PubMed
    Score: 0.870
  2. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol. 2019 07; 154(1):95-101.
    View in: PubMed
    Score: 0.838
  3. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 04 01; 30(4):551-557.
    View in: PubMed
    Score: 0.830
  4. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Curr Oncol Rep. 2016 May; 18(5):29.
    View in: PubMed
    Score: 0.678
  5. Bevacizumab in newly diagnosed ovarian cancer. Lancet Oncol. 2015 Aug; 16(8):876-8.
    View in: PubMed
    Score: 0.639
  6. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct; 15(11):1207-14.
    View in: PubMed
    Score: 0.605
  7. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014 May; 133(2):362-9.
    View in: PubMed
    Score: 0.584
  8. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 2013 Nov; 131(2):352-6.
    View in: PubMed
    Score: 0.562
  9. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8.
    View in: PubMed
    Score: 0.557
  10. Anti-angiogenic agents in ovarian cancer: dawn of a new era? Curr Oncol Rep. 2011 Dec; 13(6):450-8.
    View in: PubMed
    Score: 0.499
  11. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol. 2009 Dec; 115(3):401-6.
    View in: PubMed
    Score: 0.430
  12. Rational use of cytotoxic chemotherapy for recurrent ovarian cancer. J Natl Compr Canc Netw. 2006 Oct; 4(9):947-53.
    View in: PubMed
    Score: 0.349
  13. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 05 10; 39(14):1531-1539.
    View in: PubMed
    Score: 0.238
  14. Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol. 2020 12; 159(3):887-898.
    View in: PubMed
    Score: 0.230
  15. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78.
    View in: PubMed
    Score: 0.228
  16. Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). Gynecol Oncol Rep. 2020 May; 32:100546.
    View in: PubMed
    Score: 0.220
  17. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 12 01; 5(12):1731-1738.
    View in: PubMed
    Score: 0.217
  18. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794.
    View in: PubMed
    Score: 0.214
  19. Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol Rep. 2019 Aug; 29:118-122.
    View in: PubMed
    Score: 0.213
  20. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 11; 27(11):2124-2130.
    View in: PubMed
    Score: 0.176
  21. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res. 2017 Mar 01; 23(5):1263-1273.
    View in: PubMed
    Score: 0.173
  22. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun. 2021 09 22; 12(1):5574.
    View in: PubMed
    Score: 0.062
  23. Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions. Cancers (Basel). 2021 May 03; 13(9).
    View in: PubMed
    Score: 0.060
  24. Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 05; 161(2):581-586.
    View in: PubMed
    Score: 0.059
  25. A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020 08; 26(8):1271-1279.
    View in: PubMed
    Score: 0.056
  26. Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair-Deficient Endometrial Cancer. JCO Precis Oncol. 2020; 4:492-497.
    View in: PubMed
    Score: 0.056
  27. Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. Gynecol Oncol. 2020 02; 156(2):488-497.
    View in: PubMed
    Score: 0.054
  28. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Clin Cancer Res. 2019 10 15; 25(20):6127-6140.
    View in: PubMed
    Score: 0.053
  29. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2019 May; 38(3):230-240.
    View in: PubMed
    Score: 0.052
  30. Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Mol Cancer Ther. 2019 03; 18(3):642-655.
    View in: PubMed
    Score: 0.051
  31. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018 12 11; 25(11):2972-2980.e5.
    View in: PubMed
    Score: 0.051
  32. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 2018 11 13; 7.
    View in: PubMed
    Score: 0.051
  33. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
    View in: PubMed
    Score: 0.050
  34. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer. Clin Cancer Res. 2018 03 15; 24(6):1389-1401.
    View in: PubMed
    Score: 0.047
  35. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nat Commun. 2017 08 28; 8(1):365.
    View in: PubMed
    Score: 0.046
  36. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):13587-98.
    View in: PubMed
    Score: 0.042
  37. Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016 Mar; 5(3):e1090075.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.